Physician profile
Audrey Baker
NPI 1598296972
$7,833.44
in general payments reported to CMS, 2019-2025
43 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,311 · 2022: $1,324 · 2023: $1,748 · 2024: $1,895 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,138 · Education: $59.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,138.09 |
| Education | $59.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,419.62 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $782.51 | 2021-2025 | Trintellix |
| Lilly USA, LLC | $711.14 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $456.40 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Currax Pharmaceuticals LLC | $398.10 | 2023-2025 | Contrave, Onzetra Xsail |
| Merck Sharp & Dohme LLC | $362.13 | 2021-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.39 | 2021-2025 | Jardiance, Spiriva Respimat |
| Pfizer INC. | $313.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $300.87 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $207.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $199.32 | 2022 | |
| Exact Sciences Corporation | $197.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $170.42 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.43 | 2022-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $153.42 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $149.87 | 2021-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $143.28 | 2021 | |
| Sunovion Pharmaceuticals INC. | $131.15 | 2021-2022 | |
| Abbott Laboratories | $130.31 | 2022-2024 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $107.64 | 2021-2023 | |
| Lundbeck LLC | $105.98 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $100.16 | 2023-2025 | Auvelity |
| Corcept Therapeutics | $95.37 | 2025 | Korlym |
| Amgen INC. | $88.83 | 2023-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $78.91 | 2023-2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $63.00 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $58.15 | 2021-2024 | Nexletol |
| Astellas Pharma US INC | $55.32 | 2024 | Veozah |
| Edwards Lifesciences Corporation | $53.85 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Cranial Technologies, INC | $43.57 | 2021-2024 | Doc Band |
| Janssen Pharmaceuticals, INC | $42.35 | 2021-2025 | Spravato |
| Grifols USA, LLC | $39.25 | 2021 | |
| Ethicon INC. | $24.18 | 2023 | Monarch Platform |
| Novartis Pharmaceuticals Corporation | $21.04 | 2023 | |
| Hologic Sales and Service, LLC | $20.83 | 2023 | Thinprep 2000 Processor, Aptima |
| Supernus Pharmaceuticals, INC. | $19.45 | 2025 | Qelbree |
| Ardelyx, INC. | $18.02 | 2025 | Ibsrela |
| Lucid Diagnostics INC. | $17.76 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.95 | 2025 | |
| Pulmonx Corporation | $14.86 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Qol Medical, LLC | $13.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.50 | 2022 | |
| Neurocrine Biosciences, INC. | $11.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.